SU11274
Based on 8 publication(s) in Google Scholar
SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.
For research use only. We do not sell to patients.
- Purity: 98.82%
- CAS No.: 658084-23-2
- Formula: C28H30ClN5O4S
- Molecular Weight:568.09
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Peptidomimetic Library
HY-L033
-
Covalent Screening Library
HY-L036
-
Anti-Lung Cancer Compound Library
HY-L075
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Cancer Stem Cells Compound Library
HY-L135
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cytokine Inhibitors Library
HY-L161
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) SU11274
More- Cell Rep. 2024 Mar 27;43(4):114002. [Abstract]
- Cancer Cell Int. 2019 Jul 24:19:192. [Abstract]
- Cells. 2023 Oct 18;12(20):2481. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2023 Oct 31;1871(1):119623. [Abstract]
- Regen Ther. 2024 Dec 17:28:169-182. [Abstract]
- Pediatr Surg Int. 2019 Dec;35(12):1369-1378. [Abstract]
- University of South Dakota. 2026.
- bioRxiv. 2025 Jul 21:2025.07.16.665230. [Abstract]
Customer Validation & Images
-
RT-PCR
-
IHC
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Imaging/Staining
Biological Activity
IC50: 10 nM (Met)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
<3 μM
Compound: SU11274
|
Inhibition of cell growth in mouse BaF3 cells transfected with TPR-MET genes by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
Inhibition of cell growth in mouse BaF3 cells transfected with TPR-MET genes by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
|
[PMID: 14500382] |
| BaF3 | IC50 |
0.53 μM
Compound: 2, SU11274
|
Antiproliferative activity against mouse BAF3 cells expressing TPR-Met after 72 hrs in absence of IL-3
Antiproliferative activity against mouse BAF3 cells expressing TPR-Met after 72 hrs in absence of IL-3
|
[PMID: 21405128] |
| BaF3 | IC50 |
6.4 μM
Compound: 2, SU11274
|
Antiproliferative activity against mouse BAF3 cells expressing TPR-Met after 72 hrs in presence of IL-3
Antiproliferative activity against mouse BAF3 cells expressing TPR-Met after 72 hrs in presence of IL-3
|
[PMID: 21405128] |
| BXPC-3 | IC50 |
16 μM
Compound: 2, SU11274
|
Antiproliferative activity against human BxPC3 cells after 72 hrs
Antiproliferative activity against human BxPC3 cells after 72 hrs
|
[PMID: 21405128] |
| HepG2 | IC50 |
1.561 μM
Compound: SU, SU11274
|
Inhibition of Met-mediated tumorigenesis in HGF-stimulated human HepG2 cells assessed as impairment in anchorage-independent growth by soft agar growth assay
Inhibition of Met-mediated tumorigenesis in HGF-stimulated human HepG2 cells assessed as impairment in anchorage-independent growth by soft agar growth assay
|
[PMID: 22138308] |
| MCF7 | IC50 |
6.2 μM
Compound: 2, SU11274
|
Antiproliferative activity against human MCF7 cells after 72 hrs
Antiproliferative activity against human MCF7 cells after 72 hrs
|
[PMID: 21405128] |
| MDA-MB-231 | IC50 |
11 μM
Compound: 2, SU11274
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs
|
[PMID: 21405128] |
| MDCK | IC50 |
0.152 μM
Compound: SU, SU11274
|
Inhibition of Met-mediated scattering in HGF-stimulated human MDCK cells pre-incubated overnight prior to HGF stimulation for 24 hrs measured after 24 to 48 hrs
Inhibition of Met-mediated scattering in HGF-stimulated human MDCK cells pre-incubated overnight prior to HGF stimulation for 24 hrs measured after 24 to 48 hrs
|
[PMID: 22138308] |
| MDCK | IC50 |
0.2 μM
Compound: SU11274
|
Inhibition of Met-triggered cell scattering in HGF-stimulated MDCK cells preincubated for overnight before HGF challenge measured after 24 to 48 hrs
Inhibition of Met-triggered cell scattering in HGF-stimulated MDCK cells preincubated for overnight before HGF challenge measured after 24 to 48 hrs
|
[PMID: 22738633] |
| MKN-45 | IC50 |
1.3 μM
Compound: 2, SU11274
|
Antiproliferative activity against human MKN45 cells after 72 hrs
Antiproliferative activity against human MKN45 cells after 72 hrs
|
[PMID: 21405128] |
| NCI-H1993 | IC50 |
7.3 μM
Compound: 2, SU11274
|
Antiproliferative activity against human NCI-H1993 cells after 72 hrs
Antiproliferative activity against human NCI-H1993 cells after 72 hrs
|
[PMID: 21405128] |
| NCI-H441 | IC50 |
13 μM
Compound: 2, SU11274
|
Antiproliferative activity against human NCI-H441 cells after 72 hrs
Antiproliferative activity against human NCI-H441 cells after 72 hrs
|
[PMID: 21405128] |
| NIH3T3 | IC50 |
≥ 50 μM
Compound: 2, SU11274
|
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs
|
[PMID: 21405128] |
| NIH3T3 | IC50 |
2 μM
Compound: 2, SU11274
|
Antiproliferative activity against mouse NIH/3T3 cells expressing TPR-Met after 72 hrs
Antiproliferative activity against mouse NIH/3T3 cells expressing TPR-Met after 72 hrs
|
[PMID: 21405128] |
| SNU1 | IC50 |
7 μM
Compound: 2, SU11274
|
Antiproliferative activity against human SNU1 cells after 72 hrs
Antiproliferative activity against human SNU1 cells after 72 hrs
|
[PMID: 21405128] |
| SNU-5 | IC50 |
0.8 μM
Compound: 2, SU11274
|
Antiproliferative activity against human SNU5 cells after 72 hrs
Antiproliferative activity against human SNU5 cells after 72 hrs
|
[PMID: 21405128] |
SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC50 of < 3 μM in the absence of interleukin 3, without growth inhibition of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFβR. In addition to cell growth, SU11274 treatment significantly inhibits the migration of BaF3. TPR-MET cells by 44.8% and 80% at 1 μM and 5 μM, respectively. SU11274 inhibits HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with an IC50 of 1-1.5 μM. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC50 of 3.4 μM and 6.5 μM, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μM, and induces caspase-dependent apoptosis by 24% at 1 μM[2]. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC50 values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 658084-23-2
-
Appearance Solid
-
Molecular Weight 568.09
-
Formula C28H30ClN5O4S
-
Color White to yellow
-
SMILES
O=S(C1=CC2=C(C=C1)NC(/C2=C/C3=C(C(C(N4CCN(CC4)C)=O)=C(N3)C)C)=O)(N(C)C5=CC=CC(Cl)=C5)=O
-
Synonyms
PKI-SU11274
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion. [Abstract]2024 Mar 27;43(4):114002. PMID: 38547126 -
Cancer Cell Int
Human colorectal cancer-derived carcinoma associated fibroblasts promote CD44-mediated adhesion of colorectal cancer cells to endothelial cells by secretion of HGF. [Abstract]2019 Jul 24:19:192. PMID: 31367190 -
Cells
2023 Oct 18;12(20):2481. PMID: 37887325
SU11274 purchased from MedChemExpress. Usage Cited in: Cells. 2023 Oct 18;12(20):2481. [Abstract]
Quantification of cell proliferation by Cell Titer Glo in GC cell lines. Cells were treated with increasing doses of SU11274 (5, 10 μM) for up to 48 h.
SU11274 purchased from MedChemExpress. Usage Cited in: Cells. 2023 Oct 18;12(20):2481. [Abstract]
Immunoblot analysis showing phosphoactivation of MET, ERK 1/2, and AKT in GC cell lines treated with 10 μM SU11274 for 48 h.
SU11274 purchased from MedChemExpress. Usage Cited in: Cells. 2023 Oct 18;12(20):2481. [Abstract]
Live and dead staining of GC tumorspheres grown as 3D cocultures with CAFs and treated with 5 μM EM127 and/or 10 μM SU11274 for 48 h.
-
Biochim Biophys Acta Mol Cell Res
Hepatocyte growth factor attenuates high glucose-disturbed mitochondrial dynamics in podocytes by decreasing ARF6-dependent DRP1 translocation. [Abstract]2023 Oct 31;1871(1):119623. PMID: 37913847 -
Regen Ther
Iron-Quercetin complex enhances mesenchymal stem cell-mediated HGF secretion and c-Met activation to ameliorate acute kidney injury through the prevention of tubular cell apoptosis. [Abstract]2024 Dec 17:28:169-182. PMID: 39802634
SU11274 purchased from MedChemExpress. Usage Cited in: Regen Ther. 2024 Dec 17:28:169-182. [Abstract]
Effect of su11274 on the mRNA expression of bax, caspase 3 and bcl2 in RT-PCR.
SU11274 purchased from MedChemExpress. Usage Cited in: Regen Ther. 2024 Dec 17:28:169-182. [Abstract]
The results of H&E, PAS and IHC (Kim 1) staining treated with su11274 (0.2 mg/kg, i.p.).
-
Pediatr Surg Int
Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. [Abstract]2019 Dec;35(12):1369-1378. PMID: 31559456 -
-
bioRxiv
2025 Jul 21:2025.07.16.665230. PMID: 40777316
Solvent & Solubility
DMSO : ≥ 100 mg/mL (176.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
A chimeric protein is constructed containing the cytoplasmic domain of human c-Met fused to Glutathione S-transferase (GST) and expressed in SF9 cells. The c-Met kinase GST-fusion protein is used for an ELISA-based Met biochemical assay using the random copolymer poly(Glu:Tyr) (4:1) immobilized on microtiter plates as a substrate. IC50 value is determined with various concentrations of SU11274 in a buffer containing 5 μM ATP and 10 mM MnCl2, 50 mM HEPES (pH 7.5), 25 mM NaCl, 0.01% BSA, and 0.1 mM Na orthovanadate. The kinase reaction is performed for 5 minutes at room temperature. The extent of substrate phosphorylation is measured using horseradish peroxidase-conjugated anti-pTyr antibodies.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cells are exposed to various concentrations of SU11274 in the presence or absence of HGF for 24, 48, and 72 hours. The number of viable cells is determined using the MTT assay or trypan blue exclusion. Cell Cycle and apoptosis are measured by fluorescence-activated cell sorter analysis via propidium iodide staining and Annexin V-positive staining, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang X, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther, 2003, 2(11):1085-1092. [Content Brief]
[2]. Sattler M, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res, 2003, 63(17), 5462-5469. [Content Brief]
[3]. Ma PC, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res, 2005, 65(4), 1479-1488. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7603 mL | 8.8014 mL | 17.6028 mL | 44.0071 mL |
| 5 mM | 0.3521 mL | 1.7603 mL | 3.5206 mL | 8.8014 mL | |
| 10 mM | 0.1760 mL | 0.8801 mL | 1.7603 mL | 4.4007 mL | |
| 15 mM | 0.1174 mL | 0.5868 mL | 1.1735 mL | 2.9338 mL | |
| 20 mM | 0.0880 mL | 0.4401 mL | 0.8801 mL | 2.2004 mL | |
| 25 mM | 0.0704 mL | 0.3521 mL | 0.7041 mL | 1.7603 mL | |
| 30 mM | 0.0587 mL | 0.2934 mL | 0.5868 mL | 1.4669 mL | |
| 40 mM | 0.0440 mL | 0.2200 mL | 0.4401 mL | 1.1002 mL | |
| 50 mM | 0.0352 mL | 0.1760 mL | 0.3521 mL | 0.8801 mL | |
| 60 mM | 0.0293 mL | 0.1467 mL | 0.2934 mL | 0.7335 mL | |
| 80 mM | 0.0220 mL | 0.1100 mL | 0.2200 mL | 0.5501 mL | |
| 100 mM | 0.0176 mL | 0.0880 mL | 0.1760 mL | 0.4401 mL |
SU11274 Related Classifications
HY-12014 Related Classifications
Powered by Bioz